Serum cobalamin concentrations in dogs with leishmaniosis before and during treatment. (October 2021)

• Record Type: Journal Article
• Authors: Chatzis, M.K.; Kasabalis, D.; Steiner, J.M.; Saridomichelakis, M.N.; Suchodolski, J.S.; Xenoulis, P.G.
• Is Part Of: Comparative immunology, microbiology and infectious diseases. Volume 78(2021)
• Publication Date: 2021-10
• Subjects: Antiparasitic activity -- Cobalamin -- Dog -- Leishmania infantum -- Vitamin B12; Communicable diseases in animals -- Periodicals; Veterinary immunology -- Periodicals; Veterinary microbiology -- Periodicals; Immunology -- Periodicals; Microbiology -- Periodicals; Communicable diseases -- Periodicals; Communicable Diseases -- immunology -- Periodicals; Communicable Diseases -- veterinary -- Periodicals; Allergy and Immunology -- Periodicals; Microbiology -- Periodicals; Veterinary Medicine -- Periodicals; Immunologie -- Périodiques; Microbiologie -- Périodiques; Maladies infectieuses -- Périodiques; Communicable diseases; Immunology; Microbiology; Electronic journals; Periodicals; 636.08969
• DOI: 10.1016/j.cimid.2021.101686
• Languages: English
• ISSNs: 0147-9571

Abstract

Highlights: The first study evaluating serum cobalamin concentrations in dogs with leishmaniosis at diagnosis and during treatment. Dogs with leishmaniosis have significantly lower serum cobalamin concentrations compared to clinically healthy dogs. Increased serum cobalamin concentrations were observed during the first 2 weeks of treatment for leishmaniosis Differences in cobalamin concentrations between dogs in this study are unlikely to be the result of decreased GFR and chronic kidney disease. Abstract: Hypocobalaminemia in dogs is most commonly associated with gastrointestinal disorders leading to impaired absorption and utilization of cobalamin. The objectives of this study were to compare serum cobalamin concentrations between dogs with leishmaniosis and clinically healthy dogs, and to assess possible alterations of serum cobalamin concentrations in dogs with leishmaniosis at different timepoints during treatment. Fifty-five dogs with leishmaniosis and 129 clinically healthy dogs were prospectively enrolled. Diagnosis of leishmaniosis was based on clinical presentation, positive serology and microscopic detection of Leishmania amastigotes in lymph node aspiration smears. Twenty of the dogs with leishmaniosis were treated with a combination of meglumine antimonate and allopurinol for 28 days and serum cobalamin concentrations were measured in blood samples that were collected before initiation of treatment (timepoint 0) and on days 14 and 28. In order to estimate alterations of serum cobalamin concentrations during treatment, cobalamin concentrations were measured in blood samples from 20 out of 55 dogs with leishmaniosis at all timepoints. Serum cobalamin concentrations were significantly lower in dogs with leishmaniosis before treatment (median: 362 ng/L; IQR: 277−477 ng/L) compared to clinically healthy dogs (median: 470 ng/L; IQR: 367−632 ng/L; P = 0.0035). Serum cobalamin concentrations increased significantly in dogs with leishmaniosis on day 14 of treatment compared to timepoint 0 (P = 0.02). In the present study, serum cobalamin concentrations were significantly lower in dogs with leishmaniosis compared to clinically healthy dogs. In addition, there was an increase in serum cobalamin concentrations during treatment. The clinical significance of hypocobalaminemia in dogs with leishmaniosis remains to be determined.